Effectiveness of COVID-19 Vaccines in Patients Under Maintenance Hemodialysis

Mahallawi, Waleed H.; Ibrahim, Nadir A.; Mumena, Walaa A.

doi:10.2147/rmhp.s345686

Cited by 14 publications

(8 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The better immunogenicity of heterologous schemes could be explained by recent evidence showing that mRNA vaccines have a better humoral response when compared to adenovirus-based vaccines [ 8 , 9 , 25 – 27 ]. Furthermore, the enhanced humoral activity induced by the heterologous regimen is correlated with increased frequencies of switched and activated memory B cells recognizing the SARS-CoV-2 RBD [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients

et al. 2022

View full text Add to dashboard Cite

Background and Aim Dialysis patients are a high-risk population and have a reduced immune response to vaccination against SARS-CoV-2. The aim of this study was to assess the humoral response to homologous Gam-COVID-Vac (Sputnik V) and heterologous Sputnik V/mRNA-1273 (Moderna) vaccination in dialysis patients. The vaccination scheme depended on dose availability and the prioritization of risk populations as established by the Argentine Ministry of Health. Methods Previous COVID-19 infection was determined in symptomatic patients. Binding IgG antibodies against the spike (S) receptor-binding domain (RBD) of SARS-CoV-2 (anti-S-RBD) concentration was assessed between 3 and 16 weeks after the boost dose. Anti-S-RBD antibodies were quantified using the Abbott Diagnostics SARS-CoV-2 IgG II Quant chemiluminescent microparticle immunoassay (CMIA) on an Architect i2000 SR and an Alinity I analyzer (Abbott Diagnostics, Abbott Park, Illinois, USA). To standardize the results to WHO binding antibody units (BAU), a correction factor for Abbott arbitrary units (AU) was applied where 1 BAU/mL equals 0.142 AU, as previously established by Abbott with the WHO international standard NIBSC 20–136. Following the manufacturer’s recommendations, samples were considered reactive for anti-S-RBD when titers were above 50 AU/mL (7.2 BAU/mL). An 80% protective effect (PROT-80) against symptomatic SARS-CoV-2 infection was assumed when anti-S-RBD titers were 506 BAU/ml or higher. Charlson Comorbidity Index (CCI) score was classified as mild = 1–2, moderate = 3–4, and severe ≥ 5. Side effects were evaluated until day 7 by patients´ self-reported questionnaire. Results One hundred seven participants were enrolled [ n = 84 homologous (SpV/SpV), nn 23 heterologous (SpV/Mod)]. Median (IQR) age was 64 (50–75) years old and 79 (73.8%) were male. Additionally, 19 (22.6%) of the SpV/SpV and 4 (17.4%) of the SpV/Mod group had a prior confirmed SARS-CoV-2 infection ( p = 0.589). In the overall population, 103 patients reached seroconversion (96.3%). Anti-S-RBD IgG median titers (IQR) were higher in the heterologous [1222 (288–5680) BAU/mL] than in the homologous scheme [447 (100–1551) BAU/mL], p = 0.022. In a linear model adjusted for age, gender, days from first vaccination to boost dose and days from the boost dose to the anti-S-RBD IgG determination, previous SARS-COV-2 infection (B: 2062.2; CI95: 1231.8–2892.6; p < 0.001), and SpV/Mod vaccination scheme (B: 1294.6; CI95: 435.58–2147.6; p = 0.003) were independently associated with anti-S-RBD levels. Finally, a higher frequency of adverse effects was associated with the heterologous scheme, although they were well tolerated by all individuals. Conclusions The present study provides evidence that the homologous SpV/SpV and heterologous SpV/Mod schemes showed good e...

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…2 [ 18 , 89 ]. It is speculated that EPO and vitamin D supplementation at different stages of CKD may be crucial to maintain the efficacy of COVID-19 vaccine [ 90 ].…”

Section: Covid-19 Vaccination Of Dialysis Patientsmentioning

confidence: 99%

Clinical manifestations of COVID-19 infection in dialysis patients and protective effect of COVID-19 vaccine

Zhang

Chen

2023

Inflamm. Res.

View full text Add to dashboard Cite

Background and objective COVID-19 infection poses a special challenge to patients with dialysis patients. The purpose of this study was to evaluate the clinical manifestations of dialysis patients with COVID-19 and the protective effect of the vaccine. Methods We included 41 studies based on big data, mainly analyzing the clinical symptoms of dialysis patients with COVID-19, the proportion of severe patients before and after vaccination, and the humoral reaction of vaccine in the body. Results 6.1% to 35.7% of dialysis patients with COVID-19 developed respiratory distress symptoms and needed to be admitted to an intensive care unit for mechanical ventilation. The incidence and mortality of COVID-19 in dialysis patients before vaccination were 5.5% and 1.1%, respectively, and decreased to 4.5% and 0.6% in breakthrough infected patients. There was no statistical difference in serum conversion rates between dialysis patients and healthy controls, but the neutralizing antibody titer in the control group was 1922 (IQR 533 to 3186) AU/mL, and the neutralizing antibody titer in dialysis patients significantly decreased to 367 (IQR 171 to 1650) AU/mL ( P =0.046). Conclusions Dialysis is associated with an increased risk of severe COVID-19, and generally has a poor seroconversion response to vaccines. It also confirms the protective effect of vaccines on high-risk populations such as dialysis.

show abstract

“…It is created to prevent the interaction between spike protein and Angiotensin-Converting Enzyme -2 (ACE-2). Response to vaccination in patients with kidney impairment may be weakened along with changes in the function of immune system [18]. All kinds of vaccines protect against symptomatic if seropositive conditions are achieved [19].…”

Section: Resultsmentioning

confidence: 99%

Factors Related to Acceptance of Covid-19 Vaccine among Hemodialysis Patients in Indonesia

Perdhana

Yuliyanti²,

Chasani³

et al. 2022

J.Trop Life Science

View full text Add to dashboard Cite

Hemodialysis patients are at risk of being infected with Corona Virus Disease 2019 (Covid-19). On the other hand. End-Stage Kidney Disease (ESKD) plays a role as a predictor factor of severe Covid-19 infection. There is no data about factors that affect Covid-19 vaccine acceptance among hemodialysis patients in Indonesia. This study’s goal is to determine the factors related to Covid-19 vaccine acceptance among hemodialysis patients. A Cross-sectional study occurred in September 2021 in the hemodialysis unit at Roemani Muhammadiyah Hospital Semarang. Inclusion criteria include ESKD patients who underwent hemodialysis ≥3 months, hemodialysis frequency twice a week, communicable, and agree to join in this study. While patients with incomplete data. and being treated in the Covid-19 isolation ward are excluded from this study. Collected data analyzed using chi-square using Statistical Program for Social Science (SPSS) 18.0 version. From 87 respondents, 36 (41.4%) respondents have been vaccinated and 51 (58.6%) respondents have not been vaccinated. Hemodialysis patients with high educational level, elderly, and has undergone hemodialysis >18 months have higher acceptances of Covid-19 vaccine (57.1% and 33.9%; 60.9% and 34.4%; 51% and 38.5%, p-value 0.04; 0.027; 0.03. Prevalence Ratio (PR) = 1.7; 1.8; 1.8). While gender, marital status, and history of Covid-19 infection did not have a significant relationship to Covid-19 vaccine acceptance (p > 0.05). Educational level, elderly patients, and duration of hemodialysis have a higher acceptance of the Covid19 vaccine among the hemodialysis population. Keywords: Chronic Kidney Disease, End-Stage Kidney Disease, Immunity, SARSCoV-2, Vaccination

show abstract

Effectiveness of COVID-19 Vaccines in Patients Under Maintenance Hemodialysis

Cited by 14 publications

References 35 publications

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients

Clinical manifestations of COVID-19 infection in dialysis patients and protective effect of COVID-19 vaccine

Factors Related to Acceptance of Covid-19 Vaccine among Hemodialysis Patients in Indonesia

Contact Info

Product

Resources

About